ELAN · Elanco Animal Health Incorporat
$24.91
+0.43% last session
End-of-day data · updated 2026-07-28
Market cap
$13B
Enterprise value
$17B
Trailing P/E
—
Forward P/E
21.2
Dividend yield
—
Beta
1.68
Avg volume
6M
Employees
9K
2D change
—
5D change
2.54%
10D change
-1.63%
30D change
3.42%
60D change
6.54%
MTD change
5.48%
YTD change
12.28%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ELAN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-22
Latest call per bank · past 12 months
Morgan Stanley
Equal-Weight$26.00
+4.4% vs priceCitigroup
Buy$31.00
+24.4% vs priceJP Morgan
Overweight$30.00
+20.4% vs priceBarclays
Overweight$30.00
+20.4% vs priceUBS
Buy$27.00
+8.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-22 | Morgan Stanley | Maintains | Equal-Weight | $23.00 → $26.00 |
| 2026-06-18 | TD Cowen | Maintains | Buy | $31.00 → $32.00 |
| 2026-05-07 | Citigroup | Maintains | Buy | $30.00 → $31.00 |
| 2026-05-07 | JP Morgan | Maintains | Overweight | $28.00 → $30.00 |
| 2026-04-15 | Citigroup | Initiates | Buy | $0.00 → $30.00 |
| 2026-02-25 | Morgan Stanley | Maintains | Equal-Weight | $22.00 → $24.00 |
| 2026-02-25 | Keybanc | Maintains | Overweight | $27.00 → $29.00 |
| 2026-02-24 | Leerink Partners | Maintains | Outperform | $26.00 → $30.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 57 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 6.6% above the 50-day MA ($23.94).
- Price vs 200-day MA: Trading 9.3% above the 200-day MA ($23.34).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.05) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($26.84).
ELAN Price Chart
Loading chart for ELAN…
Fundamentals
About Elanco Animal Health Incorporat
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$56B 11.9% YTD
HLN
Haleon plc
$44B -0.4% YTD
TEVA
Teva Pharmaceutical Industries
$36B -0.4% YTD
ZTS
Zoetis Inc.
$32B -37.9% YTD
UTHR
United Therapeutics Corporation
$26B 8.3% YTD
VTRS
Viatris Inc.
$21B 43.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$18B 24.4% YTD
RDY
Dr. Reddy's Laboratories Ltd
$10B -15.6% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.